Thursday, February 11, 2016
HBM Healthcare Investments AG adds cancer immunotherapy company ARMO BioSciences to portfolio.
ARMO BioSciences announced successful completion of a $50 million Series C financing.
HBM Healthcare Investments invested $10 million in this round.
Source : reuters.com
